An effective malaria vaccine must prevent disease in a range of populations living in regions
with vastly different transmission rates and protect against genetically-diverse Plasmodium …

The Plasmodium falciparum circumsporozoite protein (PfCSP) is targeted by neutralizing
antibodies and is a focus of malaria vaccine development. In this issue of Immunity …

Background Plasmodium falciparum circumsporozoite protein (CSP) is a leading malaria
vaccine candidate antigen, known to elicit protective antibody responses in humans (RTS, S …

Background Sterile protection against malaria, most likely mediated by parasite-specific
CD8+ T cells, has been achieved by attenuated sporozoite vaccination of animals as well as …

Malaria affects∼ ¼ billion people globally and requires the development of additional tools
to aid in elimination efforts. The recently approved RTS, S/AS01 vaccine represents a …

ABSTRACT T follicular helper (TFH) cells play a crucial role in the development of long-
lived, quality-improved B cell responses after infection and vaccination. However, little is …

Immunization with radiation-attenuated sporozoites (RAS) has been shown to protect
against malaria infection, primarily through CD8 T cell responses, but protection is limited …

Efficacy data on two malaria vaccines, RTS, S and R21, targeting Plasmodium falciparum
circumsporozoite protein (Pf CSP), are encouraging. Efficacy may be improved by induction …

The circumsporozoite protein (CSP) of Plasmodium falciparum is a major surface protein,
which forms a dense coat on the sporozoite's surface. Preclinical research on CSP and …

Malaria vaccine development has been hampered by the limited availability of antigens
identified through conventional discovery approaches, and improvements are needed to …